Associate Professor David Ross MBBS, PhD, FRACP, FRCPA, is a clinical and laboratory haematologist with an academic interest in myeloid malignancies, particularly chronic myeloid leukaemia (CML) and myeloproliferative neoplasms (MPN). He completed clinical training in the Royal Adelaide Hospital, SA Pathology, and Addenbrooke’s Hospital, Cambridge before undertaking his doctoral studies in 2006-2009 with Tim Hughes, Junia Melo, and Sue Branford.
He is active in clinical trials and is on the Specialist Advisory Committee of the Australasian Leukaemia and Lymphoma Group. He is head of the Haematology Clinical Trials unit in the Royal Adelaide Hospital. He is Deputy Director of the South Australian Cancer Research Biobank, which holds >150,000 samples from blood cancer patients. He has academic affiliations with all three universities in South Australia.
He has published more than 60 peer-reviewed articles in journals including Blood, Haematologica, Leukemia, Nature, and Science Advances. Since 2017 he has been Associate Editor of Leukemia Research.
He has led clinical trials showing that around half of CML patients who achieve a stable deep molecular response on tyrosine kinase inhibitor (TKI) treatment are able to stop therapy and remain in treatment-free remission. In connection with these clinical studies he has laboratory projects focusing on the detection of rare residual leukaemic cells.
Other active projects in SAHMRI have included sequencing the mitochondrial genome in CML, and the detection of clonal haematopoiesis in CML patients in remission. His MPN-related projects are primarily conducted in the Centre for Cancer Biology (UniSA).
Click here to view publications.
Royal Australasian College of Physicians Glaxo Smith Kline Research Establishment Fellowship 2015
Leukaemia Foundation PhD Scholarship 2006-9
Royal Adelaide Hospital Nimmo Prize for Research 2005
Dr Ross’ research has been supported by funding from the NH&MRC, the Hospital Research Foundation, the Flinders Centre for Innovation in Cancer, and pharmaceutical companies.